Literature DB >> 9620550

Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice.

S T Ong1, M L Hackbarth, L C Degenstein, D A Baunoch, J Anastasi, T W McKeithan.   

Abstract

The candidate proto-oncogene BCL3 was isolated through its involvement in the t(14;19) found in chronic lymphocytic leukemia and other B-cell neoplasms. As a member of the I kappaB family, BCL3 plays a role in the immune response by interactions with the NF-kappaB family of transcription factors. In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated five lines of E mu-BCL3 transgenic mice. Transgenic animals develop normally but show splenomegaly and an accumulation of mature B cells in lymph nodes, bone marrow and peritoneal cavity. A hyperresponsive immune system is suggested by the follicular hyperplasia and plasmacytosis in lymph nodes of unimmunized animals, increased incidence of antibodies to self-antigens, and a heightened response to cross-linking of surface IgM. Statistically significant decreases in serum IgM and IgG3, but an increase in IgG1 and IgA were also observed. No lymphoid neoplasms have been identified in transgenic animals. The expansion of B cells in vivo is consistent with the overexpression of BCL3 as being one step in the multi-step process of leukemogenesis. The phenotype also suggests that BCL3 plays a part in B cell proliferation and isotype switching.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620550     DOI: 10.1038/sj.onc.1201771

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition.

Authors:  S D Westerheide; M W Mayo; V Anest; J L Hanson; A S Baldwin
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Authors:  Paula M Chilton; Thomas C Mitchell
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 3.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 4.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 5.  NF-kappaB pathways in the immune system: control of the germinal center reaction.

Authors:  Christine A Goetz; Albert S Baldwin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

7.  BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.

Authors:  Aurore Keutgens; Xin Zhang; Kateryna Shostak; Isabelle Robert; Sabine Olivier; Alain Vanderplasschen; Jean-Paul Chapelle; Patrick Viatour; Marie-Paule Merville; Françoise Bex; André Gothot; Alain Chariot
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

8.  Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures.

Authors:  Magdalene Nakou; Nicholas Knowlton; Mark B Frank; George Bertsias; Jeanette Osban; Clayton E Sandel; Helen Papadaki; Amalia Raptopoulou; Prodromos Sidiropoulos; Iraklis Kritikos; Ioannis Tassiulas; Michael Centola; Dimitrios T Boumpas
Journal:  Arthritis Rheum       Date:  2008-11

Review 9.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

Review 10.  Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription.

Authors:  Scott Palmer; Youhai H Chen
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.